Search
Sep 5
With a partnership with Intellia already in place, France's SparingVision aims to be a world leader in gene therapies and gene editing for ocular diseases
CEO Stéphane Boissel describes the company's first gene therapy program, with seeks to treat retinitis pigmentosa regardless of the...